Nevertheless, OS was significantly different according to CBF-AML status at HMA introduction with a 1-year OS of 55.0% (95%CI: 37.0–81.8) for diagnosis, 30.9% (95%CI: 16.7–57.0) for hematologic relapse and 80.0% (95%CI: 51.6–100) for molecular relapse or progression (log-rank test, p = 0.0095) (Fig. 1c). The gene discussed is CEBPZ; the disease is acute myeloid leukemia.